mated median survival was 43 weeks when treated with HBI and 42 weeks when treated with CC, but in advanced disease the estimated median survival was 15 weeks and 44 weeks respectively. Of the patients with an initial complete response, the estimated median survival was 51 weeks for HBI and 62 weeks for CC.
From these observations we suggest that sequential HBI treatment technique with local radiation boost is an efficient method of tumour control in patients with early small-cell lung cancer.
SMALL-CELL LUNG CANCER (oat cell, SCLC) is one of the most aggressive and lethal tumours known. Patients with disseminated untreated disease have a mean survival time of 7 weeks (Green et al., 1969) . Spread is so rapid via lymph and haematogeneous routes that -65% of cases (Alberto et al., 1976 ) present with disseminated disease. Common sites of metastasis are brain, liver and bone, with 20% of all patients (Ihde et al., 1979) having positive marrow aspirations when first seen. These distant metastases, whether detectable at diagnosis or developing soon after are the primary cause of treatment failuire. Therefore, for practical purposes of treatment, SCLC may be considered a systemic disease.
SCLC has a rapid doubling time of 30-45 days (Green et al., 1969; Salazar et al., 1976) which makes it responsive to chemotherapy and radiotherapy. Good responses have been obtained using either or both of these treatments. Increasingly, high-dose chemotherapy has been used as the treatment of choice for initial induction therapy. Complete responses (CR) have been recorded in as many as 740 (Cohen et al., 1.978) of limited-(lisease patients. The CR rate for patients with extensive disease has been reported in the 15°, range (Feld et al., 1979) .
The achievement of CR in SCLC patients has been well documented as increasing mnediani suirvival and (liseasefree interval (Oldham & Greco, 1980; Greco et al., 1978; Salazar & Creech, 1980; Salazar et al., 1.976) . Randomized studies are in progress to evaluate the use of non-cross-resistant chemotherapy (Pendergrass et al., 1980; Livingston & Mira, 1980; Vincent et al., 1980) or alternating vs sequential chemotherapy to achieve and maintain a complete response (Daniels etal., 1980; Aisneretal., 1980) .
The number of disease-free patients 2 years from the start of treatment remains between 7 and 300o (Salazar & Creech, 1.980 ). An effective consolidating treatment may be necessary to convert complete responders into cures. Unfortunately, improved response rates have paralleled increases in treatment-related complications and deaths due to cumulative and progressive toxicity (Greco et al., 1978 : Salazar & Creech, 1980 : Glode et al., 1980 . Hemi-body irradiation (HBI) has been reported to be valuable in the treatment of SCLC (Salazar et al., 1980; Urtasun et al., 1980; Woods et al., 1981) . The most serious toxicity from this treatment is diffuse interstitial radiation pneumonitis. In 1978, the actuarial incidence of this complication, using single radiation doses, was found to range from 29% at 8 Gy to 84% at doses of 10 Gy (Fryer et al., 1978) . However, a more recent study from the same institution, using densitycorrected absolute lung doses has observed an actuarial incidence of 500 at 8-2 Gy. The peak incidence occurred 2-3 months after irradiation (Van Dyk et al., 1981) . Therefore one of the dose-limiting factors to the single dose of radiation to both lungs is normal-lung tissue injury. Previous use of HBI has shown that if an interval of [4] [5] [6] weeks is observed between the upper and lower body regions, no serious haemopoietic injury occurs, with peripheral counts returning to normal in less than 5 weeks (Salazar et al., 1978) .
In 1978, we initiated a randomized clinical study to assess the usefulness of the sequential HBI technique in the primary management of patients with all stages of SCLC and compared it to multiple-agent sequential systemic chemotherapy (C(C). Response other lesions or new sites of malignant disease for at least 4 weeks. In patients with liver metastasis, normalization of the liver scan and blood chemistries, with 3000 reduction in the sums of measurement below the costal margin (using the umbilicus and iliac crest as body landmarks), had to be observed. These reductions in tumour size were to last at least 4 -weeks. We considered a patient in relapse on (a) appearance of new lesion, (b) reappearance of old lesions in patients with CR, and (c) for patients in PR, an increase of > 5000 in the sum of the products of the diameters of all measured tumours over the measurements at the time of maximum response.
We staged all patients at the time of entrance to the study with marrow biopsy, bone scan, liver scan and mediastinal tomography. This was repeated at the time of suspicion of relapse and before crossover.
Treatment groups
Group 1 -Cyclic chemotherapy (CC). We treated patients with a combination of 3 agents in cycles of every 28 days. Cyclophosphamide (700 mg/M2 i.v.) and CCNU (70 mg/M2 orally) were administered on Day 1 of the cycle. Methotrexate (20 mg/M2 orally) was administered on Days 18 and 21. This combination was considered at the time (1978) to represent one of the best current conventional systemic chemotherapies (Hansen et al., 1976 (Hansen et al., , 1977 . At the completion of the third cycle, the mediastinum and the original site of the primary lesion mwere irradiated to a total midplane dose of 45 Gy in 20 fractions, in a total time of 4 weeks, using parallel opposed-pair technique up to 35 Gy and then changing to oblique fields to avoid reaching the tolerance of the spinal cord. Gross non-responding metastatic disease was also irradiated at that time. Chemotherapy was re-instituted at the completion of the local radiation, and continued until either evidence of progression of the disease or after 1 year disease-free.
Group 2-Sequential hem i-body irradiation (HBI).-We treated the patients starting with the upper half-body, using anterior and posterior fields to a volume extending from the top of the head to the level of the umbilicus, with the patient lving alternately prone and supine. A single midplane dose of 8 Gy was delivered with the normal lung parenchyma shielded to receive 6 Gy corrected for lung density. We used 6 MelV photons produced by a linear accelerator at a source-to-axis distance of 200 cm and at a dose rate of 40 Gy/min using parallel and opposed anterior and posterior fields. At 6 weeks from the upper HBI, provided that the platelet counts were over 105 and the whitecell counts over 3500, we proceeded to irradiate the lower hemi-body (from the umbilicus level down to the feet) delivering 8 Gy midplane dose (calculated using the average body thickness) using the same source and dose rate as for the upper HBI. We admitted the patients to hospital for 48 h for the upper HBI procedure, and they were premedicated with prochlorperazine (Stemetil) 20 mg by mouth and diazepam (Valium) 20 mg by mouth 2 h before irradiation. Three weeks after the upper HBI. we proceeded to irradiate all patients in the mediastinum and the original site of the primary, delivering 35 Gy midplane dose in 15 fractions and in total time of 3 weeks, using parallel opposing-pair technique and shielding the cord to receive less than 30 Gy.
From March 1978 to August 1980 Mwe entered 64 previously untreated patients into the study (Table 1 ). All fulfilled the protocol requirements. Seventeen patients were unable to complete the treatment as per protocol. Eight patients on CC had evidence of disease progression before completing the initial 3 cycles of chemotherapy, and had to be transfered to HBI. Five patients on HBI had disease progression before completing the lower HBI, and had to be transferred to CC. Three patients on HBI developed diffuse interstitial radiation pneumonitis, delaying further treatments and dying of disease progression. One patient on HBI refused to proceed wNith the lowNer HBI.
Two patients on the study had sudden deaths unrelated to the tumour or the treatment (myocardial infarction and GI bleeding) at 6 and 30 days from entrance to the (Table IV) .
In those patients with early disease Non-fatal diffuse radiation interstitial pneumonitis was seen in 13% of the patients treated with upper HBI in the initial primary treatment arm, with a peak incidence averaging 6 weeks. All 4 cases were examined post mortem, and the diagnosis was proven. There was no diffuse pneumonitis in the patients switched to HBI from CC. Marrow toxicity was common with both CC and sequential HBI. We found that the incidence of marrow toxicity increased when the patients that relapsed were switched to the alternative treatment modality (Table  II) . It was not life-threatening, but mainly severe-moderate toxicity (see Table VI for definition of marrow toxicities). (Hansen et al., 1977) .
The sequential HBI technique produeed little inconvenience to the patient, since it was administered in 1 day, and there was no need for hospitalization except with the upper HBJ, which necessitated the patient being admitted to hospital for 48 h, because of moderate to severe acute GI and systemic symptoms such as nausea, vomiting, fever, and tachycardia, which usuallv lasted for 5-6 h. In our experience the patient generally becomes symptom-free and ready to begin normal activity in 24 h. This, in addition to the 1 3% incidence of interstitial diffuse pneumonitis, could be i nproved in the future by fractionating the total dose of radiation over several days.
As can be seen in 'rable VI, sequential HBI as the primary treatment has 233s acceptable marrow toxicity, but this more than doubles when HBI is used after CC. This does not preclude its use, but it emphasizes the need for extreme caution when planning to use this modality before or after CC. It is important that a second remission of 3-4 months was obtained in 60% of the patients that relapsed and were switched to either HBI or CC. It appears therefore feasible to use HBI after several courses of systemic chemotherapy, provided there is a minimum interval of 5-6 weeks for marrow recovery.
Using the overall rate and duration of response and median survival as endpoints, we found no evidence to reject the null hypothesis that CC and HBI are equally effective. However, on further analysis, considering subgroups of patients with factors that are known to affect prognosis, such as a stage, type ofresponse, whether they completed treatment or not, we have found that in advanced disease and in patients with partial responses the HBI method alone, without prior chemotherapy, appeared to be less efficient than CC alone. Furthermore, the 13% incidence of non-fatal radiation pneumonitis for the group of patients treated with HBI could make CC preferable. From the practical point of view, HBI is less cumbersome and inconvenient to the patient. Both the CC-and HBItreated patients have the same quality of survival. The incidence of extreme anorexia with gross weight loss and generalized weakness, necessitating frequent hospital admissions for intraparenteral hyperalimentation, was the same for both groups, as was the incidence of opportunistic infections. The pattern of treatment failure was the same for both treatment arms with all the necropsy material showing evidence of disease at the primary as well as distal metastatic sites, suggesting that the "boosting" dose of radiation to the local primary site was insufficient.
When analysing sequential HBI in combination with CC as a maintenance or consolidating agent, it appears that the patients able to receive both treatment modalities and achieving a second remission live longer than the patients whose treatment was not switched, though the toxicity, particularly to marrow, increased in incidence and severity. This could partially be avoided by proceeding with HBI soon after 3 cycles of induction CC.
From our observations we conclude that although sequential HBI as a primary method of treatment is generally as efficient as CC for small-cell lung cancer, the suboptimal response in patients with advanced disease prompts us to recommend its use as a consolidating or maintenance agent in combination with a more effective chemotherapy regimen. At present, in our centre the treatment for early as well as advanced disease consists of 3 months induction of cyclophosphamide (1000 mg/m2 i.v. on Day 1, Adriamycin (45 mg/M2 i.v.) Day 2 and VP-16 (180 mg/m2 i.v.) Days 1-3, in 21-day cycles with concomitant local chest irradiation to a dose of 50 Gy in 25 fractions in a total time of 51 weeks, followed by consolidation fractionated HBI at 2-5 Gy per fraction in 4 consecutive fractions for a total of 10 Gy.
The combination of CC and HBI should be considered with extreme care in viewof the increased incidence of severe marrow toxicity. Although we have not seen an increased incidence of diffuse interstitial pneumonitis at the time of treatment switch, we recommend extreme caution, particularly when using HBI with chemotherapeutic agents known to produce additive effects in normal tissue of target organs.
